Carbon Dioxide and Alzheimer’s: Promise or Risk?

anesthesia machine with monitoring screen in a hospital — Photo: Sergey Ryzhov / Shutterstock

A lab-built “brain detox” using high-dose carbon dioxide is racing ahead in trials even as other studies warn the same gas may help cause Alzheimer’s disease.

Story Snapshot

Scientists are testing brief, high-dose carbon dioxide pulses to flush toxic brain proteins into the blood.
Early human and animal studies show movement of Alzheimer’s-linked proteins, but not yet proven benefit for patients.
Other research links elevated carbon dioxide to higher Alzheimer’s risk and damaged brain blood vessels.
Experts and regulators warn against “miracle cure” devices that promise easy fixes for complex brain disease.

What the new carbon dioxide “brain detox” research shows

Researchers in the United States and Europe are studying whether short bursts of carbon dioxide in the air people breathe can push waste out of the brain. In these trials, volunteers breathe room air enriched with carbon dioxide in on–off cycles for about thirty minutes while their brain blood flow and spinal fluid are monitored. After these sessions, scientists report higher levels of proteins such as amyloid beta and phosphorylated tau in the blood. These proteins are tied to Alzheimer’s and other brain diseases, so the team believes they are being flushed from the brain into circulation.

The idea builds on a key brain system called the glymphatic pathway, which acts like a cleaning network that removes waste through fluid around blood vessels. The new studies suggest rhythmic carbon dioxide exposure increases “vasomotion,” the gentle pulsing of brain blood vessels. That pulsing appears to drive cerebrospinal fluid movement and may carry toxic proteins out. In small groups of healthy older adults and people with Parkinson’s disease, imaging showed stronger, more regular fluid waves, and blood tests found more alpha-synuclein and other brain-derived proteins after treatment.

Why some scientists see hope for Alzheimer’s — and why it is not a cure

Because amyloid beta and tau are central to Alzheimer’s disease, the research team and some commentators have suggested this carbon dioxide “pumping” method could one day help prevent or slow Alzheimer’s. A related clinical trial listed by the National Institutes of Health proposes testing whether prescribed carbon dioxide can boost protein efflux, a stand-in for waste clearance, in people with and without brain disease. Animal work pushes the idea further: rodent models exposed to high carbon dioxide atmospheres showed better movement and reduced brain damage in a Parkinson’s-like condition, hinting that controlled gas exposure might protect neurons.

Still, none of these human studies have treated people diagnosed with Alzheimer’s, measured protein buildup in their brains before and after therapy, or shown real-world gains in memory and daily function. The human trials so far mostly check whether proteins move from the brain into the blood and whether blood vessels respond rhythmically to gas changes. Even if that movement is real, scientists do not yet know if it means lasting cleanup or simply short-term shifting of disease-related proteins from one place to another. Without long studies in Alzheimer’s patients, calling this a treatment is premature.

The hard evidence that elevated carbon dioxide can harm the aging brain

Other researchers are publishing a very different warning: chronic high carbon dioxide in the blood appears linked to more Alzheimer’s disease, not less. A recent clinical study found that the partial pressure of arterial carbon dioxide in patients was directly proportional to Alzheimer’s cases. The authors argue that carbon dioxide drives brain acidosis, disrupts blood flow and oxygen, triggers inflammation, and impairs the enzymes that clear amyloid beta. In rodent models with chronic hypercapnia, they report more amyloid buildup and more tau phosphorylation, both hallmarks of Alzheimer’s pathology.

Separate work shows that the brain blood vessels of people with Alzheimer’s disease respond poorly to carbon dioxide changes. In these patients, cerebrovascular reactivity — the ability of vessels to widen and narrow when carbon dioxide rises or falls — is impaired. The vessels are often chronically over-contracted. That matters because the new “brain detox” method depends on those vessels pulsing in response to carbon dioxide in order to drive fluid movement. If the vessels in Alzheimer’s patients cannot respond normally, the very mechanism these trials rely on may be weakest in the people who most need help.

Safety fears, “miracle cure” devices, and the deep-state distrust around brain science

Beyond the lab, some companies have already tried to sell carbon dioxide rebreathing devices as wellness or brain boosters. Fact-checkers, including medical experts quoted by a major news agency, say there is no solid evidence backing these consumer devices and warn they can cause dizziness, fainting, and worsen lung disease. The United States Food and Drug Administration has repeatedly cautioned families to watch out for products that promise “scientific breakthroughs” for Alzheimer’s without rigorous trials, calling out gas therapies among other false cures. These warnings feed a broader sense that regulators and corporate interests trade on people’s fear and hope instead of supporting clear, honest science.

Many Americans on both the left and the right already feel the health system favors drug companies and elite institutions over patients. For them, it is jarring to see official science describe air pollution and elevated carbon dioxide as risk factors for Alzheimer’s, even as government-funded labs test high-dose carbon dioxide as a possible therapy. Some see this as another example of confusing, double-faced messaging from the “deep state” — one set of rules for everyday life and another set for experimental medicine. That unease will only grow if exciting headlines about “brain detox” keep spreading while basic questions on long-term safety, true benefit, and conflicts of interest stay unanswered.

What to watch next as this debate unfolds

Over the next few years, the key tests will be straightforward but hard: randomized trials in people with Alzheimer’s disease using carbon dioxide pulses, careful imaging of amyloid and tau before and after treatment, and long follow-up of thinking and daily function. Dose-response studies will also matter, because some early work suggests short, rhythmic exposure might be very different from long, constant hypercapnia. Only with this type of open, peer-reviewed data can citizens judge whether this “brain detox” is a real advance or just another lab idea that cannot survive in the real world.